Humana (NYSE:HUM) Price Target Lowered to $235.00 at Jefferies Financial Group

Humana (NYSE:HUM) had its price objective decreased by Jefferies Financial Group from $310.00 to $235.00 in a research report report published on Thursday,Benzinga reports. Jefferies Financial Group currently has a buy rating on the insurance provider’s stock.

Several other brokerages have also issued reports on HUM. Evercore ISI reduced their price target on Humana from $260.00 to $180.00 in a report on Thursday. Zacks Research cut shares of Humana from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 1st. Wells Fargo & Company lowered Humana from an “overweight” rating to a “cautious” rating in a research note on Wednesday, January 7th. Wolfe Research increased their price target on Humana from $300.00 to $325.00 and gave the stock an “outperform” rating in a research report on Thursday, January 8th. Finally, Oppenheimer set a $250.00 price target on Humana in a report on Thursday. Seven investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and five have assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $248.64.

Humana Price Performance

NYSE HUM opened at $178.99 on Thursday. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.00 and a quick ratio of 2.02. The firm has a market capitalization of $21.53 billion, a price-to-earnings ratio of 18.23, a price-to-earnings-growth ratio of 1.95 and a beta of 0.44. The company has a 50 day simple moving average of $246.13 and a 200-day simple moving average of $261.18. Humana has a 52-week low of $169.61 and a 52-week high of $315.35.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, February 11th. The insurance provider reported ($3.96) EPS for the quarter, beating analysts’ consensus estimates of ($4.01) by $0.05. Humana had a net margin of 0.92% and a return on equity of 11.43%. The firm had revenue of $32.64 billion for the quarter, compared to the consensus estimate of $32.08 billion. During the same period in the previous year, the firm posted ($2.16) earnings per share. The firm’s revenue was up 11.3% on a year-over-year basis. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. Equities research analysts predict that Humana will post 16.47 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Sound View Wealth Advisors Group LLC raised its stake in Humana by 3.5% in the 4th quarter. Sound View Wealth Advisors Group LLC now owns 1,060 shares of the insurance provider’s stock valued at $272,000 after acquiring an additional 36 shares during the period. Unison Advisors LLC grew its position in Humana by 0.4% during the third quarter. Unison Advisors LLC now owns 10,137 shares of the insurance provider’s stock worth $2,646,000 after buying an additional 37 shares in the last quarter. CoreCap Advisors LLC lifted its position in Humana by 54.4% during the fourth quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider’s stock worth $27,000 after purchasing an additional 37 shares during the period. Insigneo Advisory Services LLC raised its position in shares of Humana by 3.0% in the 3rd quarter. Insigneo Advisory Services LLC now owns 1,484 shares of the insurance provider’s stock valued at $386,000 after buying an additional 43 shares in the last quarter. Finally, Columbus Macro LLC raised its position in Humana by 5.5% during the fourth quarter. Columbus Macro LLC now owns 821 shares of the insurance provider’s stock valued at $210,000 after purchasing an additional 43 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors.

Humana News Roundup

Here are the key news stories impacting Humana this week:

• Positive Sentiment: Q4 results marginally beat expectations: Humana reported EPS of ($3.96) vs. consensus ($4.01) and revenue of $32.64B, with revenue up ~11% year/year — evidence the business still has top‑line momentum. Humana Reports Fourth Quarter 2025 Financial Results
• Positive Sentiment: Medicare Advantage membership is growing fast and CenterWell continued to drive revenue — management flagged a ~25% MA membership increase for 2026, which supports medium‑term growth expectations even as margins recover. Humana outlines 25% Medicare Advantage membership growth
• Neutral Sentiment: Some analysts remain constructive or neutral after the print — Jefferies kept a Buy stance while lowering its target to $235 (still well above the current price), creating a counterbalance to the downgrades. Jefferies lowers price target to $235
• Neutral Sentiment: TD Cowen maintained a Hold with a $173 target, signaling cautious tone from some Street strategists even as views diverge. TD Cowen Hold rating
• Negative Sentiment: FY‑2026 guidance was cut materially: Humana set EPS guidance of 9.00 vs. the Street ~12.03, citing lower quality Star Ratings and margin pressure — the guidance shortfall is the principal driver of the recent selloff and investor concern. Humana forecasts 2026 profit below estimates (Reuters)
• Negative Sentiment: Q4 GAAP loss widened and margins are under stress from rising MA medical costs and Star Ratings pressure — investors are focused on near‑term profitability risk even as membership rises. Humana Reports $796 Million Loss (Forbes)
• Negative Sentiment: Multiple firms cut price targets and slashed forecasts after the results and outlook — Evercore, Leerink, Cantor and others trimmed targets (some now near or below the stock), increasing downside risk from analyst revisions. Analysts slash forecasts after Q4 (Benzinga)
• Negative Sentiment: Shares recently hit a 52‑week low after the weak outlook; today’s uptick appears to be a short‑term rebound as investors parse the offset between growth and profit risk. Humana hits 52-week low (Benzinga)

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.